2 results about "Vascular hypertension" patented technology

The application discloses a polynucleotide sequence for simultaneously reducing blood fat and blood pressure and application thereof. Cell and mouse experiments show that the application can significantly inhibit the expression levels of multiple blood fat and blood pressure molecular targets such as proprotein convertase subtilisin / kexin type 9 (PCSK9), angiotensinogen (AGT) and beta-hydroxy-beta-methylglutaryl-coenzyme a reductase (HMGCR), thereby reducing the blood fat and blood pressure levels of a related disease model mouse. The application is expected to be applied to treating related cardiovascular and cerebrovascular diseases complicated with high blood fat and high blood pressure symptoms.

The invention discloses a shark source single-domain antibody targeting LRP6 and application of the shark source single-domain antibody. The single-domain antibody has an amino acid sequence as shown in SEQ ID NO: 1, shows nanomole-level high affinity to LRP6 protein, has an affinity constant KD value of 1.8 * 10 <-9 > M, shows excellent physical and chemical stability, has a thermal denaturation temperature as high as 75.6 DEG C, and can still retain 92% or more of binding activity after being incubated for 2 hours under a strong acidic condition. Meanwhile, the antibody has high specificity, and the cross reaction rate of the antibody with homologous protein LRP5 and homologous protein LDLR is lower than 4%. The invention also provides a composition for reducing hypertension, hyperglycemia and hyperlipidemia, which contains the single-domain antibody and a specific natural plant extract composite component. Experiments show that the composition can synergistically act on a plurality of pathological links of the metabolic syndrome, the symptoms of hyperglycemia, hyperlipidemia and hypertension are remarkably improved in an animal model, the effect is better than that of a single component and a traditional control drug, and a brand new multi-target treatment scheme is provided for prevention and treatment of the metabolic syndrome.